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Abstract Treatment options for primary and metastatic
renal cancer are increasing. Accurate data from the
pathological examination of renal cancer specimens aid
clinicians in stratifying patients for surveillance and
adjuvant therapies. This review focuses on biomarkers
in diagnosis, prognosis and prediction of the biologic
behavior of renal tumors which should be recorded in
pathology reports and which are under investigation.
Special emphasis is given to the use of immunohisto-
chemical markers in differential diagnosis of various
renal tumor subtypes. The relevance of cytogenetic and
molecular findings is also discussed. The review in-
cludes the 2012 International Society for Urological
Pathology Consensus conference recommendations.
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Introduction
Biomarkers in renal cell carcinoma (RCC) are of help in
pathological diagnosis, classifying new entities, and include
predictive and prognostic markers. Immunohistochemistry
allows the characterization of renal tumor subtypes, whereas
novel molecular analyses are mainly used to characterize
specific molecular pathways involved in different tumor sub-
types. They are also useful to identify potential therapeutic
targets. This article will review the key prognostic factors with
an emphasis on the use of immunohistochemical markers in
routine practice. The review is intended to complement the
International Society of Urological Pathology (ISUP) confer-
ence on renal cancer held in Vancouver in 2012 [1, 2].
Old and new subtypes of renal cell neoplasms
In adults, the main morphotype of RCC, when correctly
classified, is the strongest prognostic biomarker in addition
to tumor stage and grade [3, 4]. The current World Health
Organization Classification of Renal Tumors was established
2004 [5]. In adults, the main subtypes are clear cell, papillary,
chromophobe, collecting duct, and unclassified RCC, but
various other subtypes have been recognized in the 2004
WHO classification, including mixed epithelial and stromal
tumors (MEST), mucinous tubular and spindle-cell carcinoma
(MTSC), and translocation cancer. Oncocytoma,
angiomyolipoma, and metanephric adenoma are considered
benign renal neoplasms. At the ISUP conference, a consensus
was reached to recognize five entities as new distinct epithelial
tumors: tubulocystic RCC, acquired cystic disease-associated
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RCC, clear cell (tubulo) papillary RCC, the MiT family trans-
location RCCs (including t(6;11) RCC), and hereditary
leiomyomatosis RCC syndrome-associated RCC. Thyroid-
like follicular RCC, succinate dehydrogenase B deficiency-
associated RCC and ALK translocation RCC were regarded
as emerging new entities (Figs. 1, 2 and 3) [1]. Subtyping of
papillary RCC (types 1 and 2) provides additional prognostic
information. For the time being, the oncocytic variant of
papillary RCC is not considered as a distinct entity. Clear cell
(tubulo)papillary RCC is associated with a more favorable
outcome. Multicystic clear cell RCC is considered as a neo-
plasm of lowmalignant potential within the group of clear cell
RCC. The hybrid oncocytic chromophobe tumor occurs in
Birt-Hogg-Dubé Syndrome, in renal oncocytosis and also as a
sporadic neoplasm. Hybrid oncocytic chromophobe tumors
are indolent tumors grouped, at least for the time being, in the
chromophobe RCC category. Epitheloid angiomyolipoma is
nowadays considered a potentially malignant variant of
angiomyolipoma, becausemetastatic disease has been reported
in some patients with this specific subtype of angiomyolipoma.
Cystic nephroma and mixed epithelial and stromal tumor
are seen as a morphological spectrum within a single tumor
type [1].
Perinephric fat invasion as a staging parameter
The 2009 TNM system has minor changes compared to the
2002 TNM system, notably in clarifying that infiltration of
renal sinus (peripelvic) fat is part of perinephric tissue involve-
ment in the pT3 tumor category [6, 7]. Perinephric fat invasion
is prognostically relevant, as it is associated with a significant
decrease in 5-year overall survival [8]. Perinephric fat inva-
sion was defined at the 2012 ISUP conference as either the
tumor touching the fat or extending with irregular tongues into
the perinephric tissue, with or without desmoplasia [9]. Im-
portantly, recent studies have shown the relevance of renal
sinus invasion in renal cancer [10, 11]. The frequent renal
sinus invasion in early-stage tumors has been overlooked for
many years, but has significant prognostic implications. Renal
sinus invasion is present when the tumor is in direct contact
with the fatty tissue or the loose connective tissue of the sinus.
Involvement of any endothelial lined spaces within the renal
sinus is considered as renal sinus invasion, regardless of the
size of the vascular space [9].
Tumor grade, sarcomatoid differentiation, and necrosis
as prognostic biomarkers of renal cancer
The Fuhrman grading system has been in use for over 30 years
and is still the most widely utilized grading system for renal
cancer [12]. Nonetheless, it has not evolved over the years to
accommodate our increasing understanding of the nature and
biological spectrum of renal carcinoma. Furthermore, its use
has become controversial, as it is increasingly recognized that
its application is not without problems [13, 14]. In addition,
the grading system has not been validated for many of the
morphotypes of renal cell carcinoma. In view of the problems
associated with the application of Fuhrman grading, a new
grading system was endorsed at the recent ISUP consensus
conference [3]. Nucleolar prominence defines grades 1 to 3 of
clear cell and papillary RCCs, whereas extreme nuclear pleo-
morphism or sarcomatoid and/or rhabdoid differentiation de-
fines grade 4 tumors. The ISUP grading system was endorsed
as a prognostic parameter for clear cell renal cell carcinoma. In
addition, a consensus was reached that chromophobe RCC
should not be graded [15–17], as irregular nuclei, prominent
nucleoli, and nuclear pleomorphism are inherently present in
chromophobe RCC, even in cases with good prognosis [3].
Different grading systems for chromophobe RCC have
been proposed [15], but these were not endorsed at the 2012
ISUP consensus conference. Sarcomatoid and/or rhabdoid
differentiation and tumor necrosis were accepted as useful
Fig. 1 Mucinous tubular and
spindle-cell carcinoma showing
classical pattern with elongated
tubules, spindle-cell areas, and
stromal mucin
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additional histopathologic prognostic parameters [4].
Sarcomatoid or rhabdoid differentiation should be mentioned
in pathology reports of all RCC subtypes. For a correct tumor
classification, the underlying carcinoma subtype should be
reported, because this can be recognized for all main subtypes.
If the underlying carcinoma subtype cannot be recognized in
sarcomatoid RCC, the tumor should be classified as a grade 4
unclassified carcinoma with a sarcomatoid component. Tumor
necrosis is considered of prognostic significance and the
amount of necrosis should be quantified in clear cell RCC.
In contrast, intratumoral microvascular invasion should not be
included as a staging criterion for RCC [4, 9].
RCC is considered to be susceptible to the innate and
adaptive immune responses of the host because a small subset
of patients with advanced disease achieves spontaneous or
immunotherapy-induced complete remission. The cellular
and molecular mechanisms underlying these complete remis-
sions are not completely understood, although a variety of
inflammatory cells including T and Natural killer (NK) cells
have been identified in RCC lesions. Local immunoregulatory
processes may have an impact on disease progression and
therefore on survival of patients with primary clear cell renal
cell carcinoma. Earlier data have shown that a high number of
tumor-infiltrating lymphocytes and/or macrophages are asso-
ciated with poor prognosis [18–20].
Differential diagnosis of renal cell neoplasms
using immunohistochemical biomarkers
Most renal cancer subtypes have a characteristic immunohis-
tochemical staining profile that helps in the correct tumor
classification. It has been shown that upregulation of CD10
and Pax 2 expression is due to VHL inactivation in clear cell
RCC [21, 22], while CAIX is also consistently expressed due
to its regulation by the VHL protein [23, 24]. Papillary RCC
type 1 stains for vimentin, broad spectrum keratins, CK7,
AMACR and RCC marker, but not for CD117, kidney-
specific cadherin, and parvalbumin. Papillary RCC type 2
has variable staining patterns. Whereas papillary type 1 RCC
frequently show diffuse CK7 immunoreactivity, papillary type
2 RCC are less often positive for CK7, in a staining pattern
comparable to that of clear cell RCC with only focal CK7
expression. Chromophobe RCC are negative for vimentin
(Table 1), but show diffuse reactivity for E-cadherin, kidney-
specific cadherin, parvalbumin, CD117, EMA, broad spec-
trum keratins, and CK7 [1, 4]. To differentiate between benign
oncocytoma and chromophobe RCC, specifically its eosino-
philic variant, is difficult as these tumors have overlapping
histological and immunohistochemical characteristics. CK7 is
the best marker to differentiate between these two tumor
entities. Most chromophobe RCCs show membranous CK7
expression in tumor cell clusters or in the majority of tumor
cells while oncocytoma is typically negative or at most focally
positive in scattered cells [25, 26]. Other biomarkers useful for
this differential diagnosis are summarized in Table 2.
Fig. 2 New tumor entity:
leiomyomatous renal cell
carcinoma. Note nests and tubules
lined by clear cells embedded in
smooth muscle
Fig. 3 New tumor entity: Renal cell carcinoma in end-stage renal dis-
ease. Note cytoplasmic vacuolation
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Collecting duct carcinomas often show immunoreactivity
for EMA, CK7, high molecular weight keratin, Pax 2 and/or
Pax 8 [27] (Table 3). Pax 2 and/or Pax 8 are frequently
expressed in different renal carcinoma subtypes and represent
useful markers in the differential diagnosis of a primary renal
carcinoma, although expression patterns need to be interpreted
in conjunction with other markers. For instance, expression of
Pax 8 has been reported in primary pancreatic neuroendocrine
tumors, which can mimic metastatic RCC [28]. Distinction
from RCC will therefore require additional support, including
the lack of expression of neuroendocrine markers for a diag-
nosis of RCC. There is consensus that TFE3 and TFEB
immonostains should be requested in order to diagnose RCC
in a young patient or when histological appearances are sug-
gestive of the translocation subtype of RCC [4].
Epitheloid angiomyolipoma closely resembles RCC [3,
29]. Positive immunoreactivity for HMB45, melan-A and
SMA, and absence of expression of keratins, helps in the
diagnosis of angiomyolipoma [30]. Metanephric adenoma
can be mistaken for type 1 papillary RCC. The former shows
positive immunostaining for WT1, CD57, and absence of
reactivity for AMACR [31]. AMACR, CK7, WT1, and
CD57 are therefore useful to distinguish metanephric adeno-
ma from papillary RCC (Table 4).
Molecular prognostic biomarkers
Biomarkers for potential prognostication of RCC include
molecules in intracellular pathways and/or specific DNA al-
terations. Most of them have not entered clinical practice.
Clear cell RCC is characterized by loss of chromosome 3p
andmutations of the von Hippel Lindau (VHL) gene [32].VHL
mutations have been reported in the majority of sporadic clear
cell renal carcinomas [33]. These mutations can impact on the
hypoxia inducible factor (HIF) pathway and their existence
provides the theoretical molecular explanation for the success
of HIF targeted treatment strategies in some patients with clear
cell RCC (see below) [34, 35]. Dysregulation of HIF leads to
upregulation of the expression of downstream molecules,
including Carbonic anhydrase 9 (CAIX). One study found
an association between CAIX expression and grade of clear
cell RCC [36]. Diminished CAIX expression was indepen-
dently correlated with poor survival in advanced renal cell
cancer patients [37]. Some other chromosomal abnormalities
may have prognostic value, such as loss of chromosome 9p in
clear cell RCC, which is associated with a significantly poorer
cancer specific survival [38, 39]
A relatively new finding is the frequent polybromo-1
(PBRM1) and BAP 1 mutation on chromosome 3p in a sur-
prisingly high percentage of clear cell RCC [40]. Loss of
PBRM1 protein expression product BAF180 was shown to
be associated with advanced tumor stage and worse patient
outcome [41]. All of these newly identified mutations target
Table 2 Biomarker in chromophobe RCC and oncocytoma
Biomarker Chromophobe RCC Oncocytoma
CK7 + −/focal +
MOC31 + −
EpCam + −
Caveolin-1 + −
EABA − +
CD82 + −
S100A1 − +
Parvalbumin + +
Ksp cadherin + +
CD117 + +
Table 3 Biomarker for poorly differentiated carcinomas
Antibody RCC,
unclassified
Collecting duct
carcinoma
Urothelial
carcinoma
CK7 −/+ + +
CK20 − − (rarely focal+) +/−
P63 − − (rarely+) +
RCC +/− − −
Vimentin +/− + −/+
CD10 +/− − −/+
CK5/6 − − +/−
INI1 + + +
Ulex-1 − + −/+
PAX8 +/− + −/rarely +
PAX2 +/− +/− −
GATA3 −/(rarely focal +) − +
Table 1 Biomarkers in clear cell and chromophobe RCC
Biomarker Clear cell RCC Chromophobe RCC
CK7 − (focal) +
RCC marker + −
CD10 + −
Vimentin + −
CD117 − +
Parvalbumin − +
E-cadherin − +
EMA + +
MUC1 + +
CK20 − −
AMACR − −
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genes which are responsible for chromatin remodeling. Future
studies will help to understand the tumor suppressor gene
network between VHL and the other genes on chromosome
3p. Compared to other solid tumors, intratumoral heterogene-
ity of driver gene mutations is very pronounced within prima-
ry RCC as well as between primary tumors and their metas-
tases [42, 43]. The process of clonal evolution of renal cancer
cells is very complex, and this has potential consequences for
tumor progression, development of resistance against targeted
therapies, with clinical impact.
Papillary RCC is characterized by numerical abnormalities,
often trisomies of chromosomes 7 and 17 [44]. Chromophobe
RCCs harbor multiple numerical losses of chromosomes 1, 2,
6, 10, and 17 [45]. Translocation RCCs are defined by trans-
locations involving chromosome Xp11.2, resulting in TFE3
gene fusions [46]. Another variant of translocation associated
RCC is characterized by fusion of the TFEB gene on chromo-
some 6p with the alpha gene on 11q12, which leads to
expression of the TFEB protein [47, 48].
Cytogenetics and novel molecular technologies are rarely
used in renal carcinoma diagnosis, but have contributed to tumor
classification, understanding the histogenesis and the genotype/
phenotype correlation in RCC. Some groups recommend a panel
of fluorescence in situ hybridization (FISH) probes for the
differential diagnosis of RCC. For instance, numerical abnor-
malities of chromosomes 7 and 17 on FISH favor a diagnosis of
papillary RCCs over clear cell RCC. The value of FISH in
diagnosing a translocation RCC with equivocal immunohisto-
chemical results has recently been emphasized [49].
Predictive markers in renal cancer
Predictive markers provide information on whether a particu-
lar cancer will respond to or be resistant to a specific type of
therapy. In contrast to other solid tumors, e.g., lung and
colorectal cancer or melanoma, use of predictive biomarkers
for clinical stratification and management planning has not yet
entered routine practice in metastatic renal cancer [4, 50, 51].
In 2007, six new agents, which target complex molecular
pathways regulating tumor angiogenesis and cell proliferation
and survival, have been approved. These treatments have
significantly improved survival times in metastatic renal cell
carcinoma [52]. Patients with advanced clear cell RCC receive
VEGF pathway antagonists, e.g., sunitinib or pazopanib.
Analysis of VHL mutation status, plasma CAIX, VEGF,
sVEGFR2, tissue inhibitor of metalloproteinase 1 (TIMP-1),
and Rasp21 has been performed in the TARGET trial com-
paring sorafenib with placebo in advanced RCC [53]. No
predictive markers were identified [54, 55]. Choueiri and
colleagues evaluated tumor CAIX expression using immuno-
histochemistry in patients treated with antiangiogenic thera-
pies [56]. While CAIX expression was neither prognostic nor
predictive of response to sunitinib, for sorafenib-treated pa-
tients, high CAIX expression (>85 %) was associated with
decreased tumor size in response to treatment.
MicroRNAs (miRNAs, miRs) are small (19–25 nucleo-
tides), non-coding RNAs that play an important role in apopto-
sis, survival, proliferation, and differentiation processes, by the
post-transcriptional regulation of gene-expression. An increas-
ing body of evidence suggests that micro RNA’s play a crucial
role, not only as oncogenic or tumor-suppressive molecules in
cancer initiation, progression and metastasis, but also in resis-
tance to chemotherapy or other systemic therapies. Therefore,
miRNA’s might constitute potential prognostic and/or predic-
tive biomarkers. Prognostic miRNA expression patterns have
recently been identified in RCC tissues [57, 58]. High levels of
miR-210 were noticed in chemotherapy resistant ccRCC pa-
tients [59]. Downregulation of miR-141 was correlated with
lack of response to sunitinib treatment in ccRCC patients, when
compared to the expression profile in responding patients [60].
Gamez-Pazo and other groups provided evidence that the re-
sponse of metastatic ccRCC patients to TKI inhibitors is corre-
lated with a miRNA profile in patient serum [61–63].
Table 4 Biomarker for renal tu-
mors with papillary or
tubulopapillary architecture
Antibody Papillary
RCC
Collecting duct
carcinoma
Metanephric
adenoma
Mucinous tubular and
spindle-cell carcinoma
Clear cell
papillary RCC
CK7 + + − (only
focal)
+ + (diffuse)
CD10 + − − −/+ −
RCC + − − variable −/+
AMACR + − −/+ + −
EMA/MUC1 + + − (may be
focal)
+ +
WT1 − − + − −
CD57 − No data + − No data
Ulex-1 − + − − No data
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Conclusion
Correct tumor classification, histologic grading and systemat-
ic examination of radical nephrectomy or tumorectomy spec-
imen are essential for patient management. Tumor stage,
tumor type, and tumor grade are robust and independent
histopathological prognostic factors, which should be
routinely included in pathology reports. Evidence for
other prognostic biomarker is lacking. In contrast to
other cancers, e.g., lung and colorectal carcinomas or
melanoma there are at present no predictive molecular
biomarker, suitable for routine use. Future investigation
of recently identified novel molecular alterations and
tumor suppressor networks in clear cell RCC will help
to clarify the biological relevance of different molecular
signaling pathways in predicting therapy response.
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